Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The page now presents the completed Phase 2 pembrolizumab study record, including its eligibility criteria, study design, outcomes, results-related dates, investigators, and a study protocol document.
    Difference
    44%
    Check dated 2026-11-07T14:14:26.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T15:22:30.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice announces that NIH content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during a transition.
    Difference
    1%
    Check dated 2026-10-24T17:07:28.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T16:50:25.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T17:17:19.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the usual content with an access-block message and standard site chrome.
    Difference
    17%
    Check dated 2026-09-19T18:30:46.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.